Besides mediating tamoxifen resistance, c-Src also drives epirubicin resistance in multidrug-resistant human luminal-type breast cancer MCF-7 cells (MCF-7/ADR) and in MDA-MB-468/EPR cells. Here, SRC is linked to breast carcinoma.